US 11,654,166 B2
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Sandra P. Morales, Sydney (AU); Gillian Mearns, Sydney (AU); Deborah A. Rankin, Sydney (AU); and Frenk Smrekar, Ljubjlana (SI)
Assigned to ARMATA PHARMACEUTICALS, INC., Marina del Rey, CA (US)
Appl. No. 16/959,666
Filed by Armata Pharmaceuticals, Inc., Marina del Rey, CA (US)
PCT Filed Jan. 2, 2019, PCT No. PCT/US2019/012114
§ 371(c)(1), (2) Date Jul. 1, 2020,
PCT Pub. No. WO2019/136109, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/731,775, filed on Sep. 14, 2018.
Claims priority of provisional application 62/678,611, filed on May 31, 2018.
Claims priority of provisional application 62/613,050, filed on Jan. 2, 2018.
Prior Publication US 2021/0077551 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/76 (2015.01); A61P 31/14 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 35/76 (2013.01) [A61K 9/0019 (2013.01); A61P 31/14 (2018.01); A61K 45/06 (2013.01)] 34 Claims
 
1. A bacteriophage composition substantially free of bacterial components comprising two or more obligately lytic bacteriophages, wherein at least one of the bacteriophages comprises a nucleotide sequence having at least 90% identity to any one of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.